文献速递肾移植

多中心研究:移植HCV感染肾脏后使用格卡瑞韦/哌仑他韦治疗

Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection.
PubMed 文献 · J Am Soc Nephrol · 2020-08-25

在7个中心的前瞻性试验中,将30例HCV病毒血症死亡供者的肾脏移植给HCV阴性受者,移植后3天开始8周格卡瑞韦/哌仑他韦治疗。所有30例受者均获得持续病毒学应答,无严重不良事件归因于HCV或治疗,6个月时移植肾功能良好。

要点

  • HCV病毒血症供肾移植给HCV阴性受者后,8周格卡瑞韦/哌仑他韦方案安全有效。
  • 所有30例受者均获得持续病毒学应答(治疗结束后12周HCV RNA检测不到)。
  • 6个月时中位血肌酐1.2 mg/dl,中位eGFR 57 ml/min/1.73 m²,移植肾功能良好。

核心结论

  • 多中心试验表明,将30例HCV病毒血症肾脏移植给HCV阴性受者,并早期启动8周格卡瑞韦/哌仑他韦方案,具有安全性和有效性。

研究设计与样本

  • 前瞻性开放标签试验,在7个中心进行,计划移植30例HCV病毒血症死亡供者的肾脏给HCV未感染受者,移植后3天开始每日一次格卡瑞韦/哌仑他韦共8周。

主要发现

  • 筛查76例患者,入组63例,其中30例接受了HCV病毒血症死亡供者肾脏移植(中位肾脏供者风险指数53%),移植时间为2019年5月至2019年10月。
  • 从同意到移植HCV病毒血症供肾的中位时间为6.3周。
  • 所有30例受者均获得持续病毒学应答。
  • 1例受者在获得持续病毒学应答后4个月死于脓毒症并发症。
  • 未发现任何患者出现可能与HCV感染或格卡瑞韦/哌仑他韦治疗相关的严重不良事件。

临床怎么用

  • 对于HCV阴性等待肾移植的患者,可考虑接受HCV病毒血症死亡供者的肾脏,并在移植后早期启动8周格卡瑞韦/哌仑他韦治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Single-center trials and retrospective case series have reported promising outcomes using kidneys from donors with hepatitis C virus (HCV) infection. However, multicenter trials are needed to determine if those findings are generalizable. METHODS: We conducted a prospective trial at seven centers to transplant 30 kidneys from deceased donors with HCV viremia into HCV-uninfected recipients, followed by 8 weeks of once-daily coformulated glecaprevir and pibrentasvir, targeted to start 3 days posttransplant. Key outcomes included sustained virologic response (undetectable HCV RNA 12 weeks after completing treatment with glecaprevir and pibrentasvir), adverse events, and allograft function. RESULTS: We screened 76 patients and enrolled 63 patients, of whom 30 underwent kidney transplantation from an HCV-viremic deceased donor (median kidney donor profile index, 53%) in May 2019 through October 2019. The median time between consent and transplantation of a kidney from an HCV-viremic donor was 6.3 weeks. All 30 recipients achieved a sustained virologic response. One recipient died of complications of sepsis 4 months after achieving a sustained virologic response. No severe adverse events in any patient were deemed likely related to HCV infection or treatment with glecaprevir and pibrentasvir. Three recipients developed acute cellular rejection, which was borderline in one case. Three recipients developed polyomavirus (BK) viremia near or >10,000 copies/ml that resolved after reduction of immunosuppression. All recipients had good allograft function, with a median creatinine of 1.2 mg/dl and median eGFR of 57 ml/min per 1.73 m2 at 6 months. CONCLUSIONS: Our multicenter trial demonstrated safety and efficacy of transplantation of 30 HCV-viremic kidneys into HCV-negative recipients, followed by early initiation of an 8-week regimen of glecaprevir and pibrentasvir.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Sise ME, Goldberg DS, Kort JJ, et al. Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection. J Am Soc Nephrol. 2020. PMID: 32843477. doi:10.1681/ASN.2020050686

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。